← Back to Search

Unknown

Dose Level 1 for Idiopathic Pulmonary Fibrosis

Phase 2
Waitlist Available
Research Sponsored by Nitto Denko Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to visit 14 (day 169)
Awards & highlights

Study Summary

This trial is testing a new drug for safety, tolerability, and how well it works in people with IPF.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to visit 14 (day 169)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to visit 14 (day 169) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Discontinuing Study Treatment Due to TEAEs
Secondary outcome measures
Absolute and Relative Change in FVC (L) From Baseline to Week 24
Absolute and Relative Change in ppFVC (%) From Baseline to Week 24
Change in DLCO and DLCO Corrected for Hemoglobin From Baseline to Week 24
+12 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Dose Level 2Experimental Treatment1 Intervention
ND-L02-s0201 90mg
Group II: Dose Level 1Experimental Treatment1 Intervention
ND-L02-s0201 45mg
Group III: PlaceboPlacebo Group1 Intervention
Control Arm
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ND-L02-s0201 (High Dose)
2018
Completed Phase 2
~130
ND-L02-s0201 (Low Dose)
2018
Completed Phase 2
~130

Find a Location

Who is running the clinical trial?

Nitto Denko CorporationLead Sponsor
5 Previous Clinical Trials
423 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Florida
California
How old are they?
65+
What site did they apply to?
University of California, San Francisco, Medical Center at Parnassus
Central Florida Pulmonary Group, PA
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF
2018. "JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03538301.
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top